(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.23%) $83.66
(-1.16%) $1.619
(0.10%) $2 349.60
(-0.07%) $27.52
(0.25%) $924.40
(0.36%) $0.935
(0.67%) $11.02
(0.14%) $0.800
(-0.07%) $92.11
0.00% $ 1.100
@ $1.160
Emitido: 14 feb 2024 @ 09:35
Retorno: -5.17%
Señal anterior: feb 13 - 09:30
Señal anterior:
Retorno: 0.00 %
Live Chart Being Loaded With Signals
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases...
Stats | |
---|---|
Volumen de hoy | 351 535 |
Volumen promedio | 1.47M |
Capitalización de mercado | 192.92M |
EPS | $0 ( 2024-03-05 ) |
Próxima fecha de ganancias | ( $-0.0300 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -7.86 |
ATR14 | $0.00300 (0.28%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-27 | Rojkjaer Lisa | Buy | 187 500 | Employee Stock Option (right to buy) |
2024-03-27 | Rojkjaer Lisa | Buy | 0 | |
2024-02-28 | Schorno Dean L | Buy | 78 500 | Employee Stock Option (right to buy) |
2024-02-28 | Schorno Dean L | Buy | 62 500 | Employee Stock Option (right to buy) |
2024-02-28 | Santos David A | Buy | 80 000 | Employee Stock Option (right to buy) |
INSIDER POWER |
---|
93.23 |
Last 98 transactions |
Buy: 9 654 000 | Sell: 304 047 |
Volumen Correlación
Rigel Pharmaceuticals Inc Correlación
10 Correlaciones Más Positivas | |
---|---|
CRNC | 0.963 |
ROIV | 0.959 |
NLSP | 0.958 |
MLCO | 0.954 |
MOMO | 0.954 |
FXCO | 0.951 |
CTSO | 0.949 |
APAC | 0.948 |
VRDN | 0.946 |
BRAC | 0.945 |
10 Correlaciones Más Negativas | |
---|---|
GRIN | -0.954 |
PIII | -0.939 |
RIVN | -0.938 |
SNPX | -0.925 |
OP | -0.924 |
SWAV | -0.923 |
ZENV | -0.923 |
LAWS | -0.919 |
NAKD | -0.916 |
ENPH | -0.916 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Rigel Pharmaceuticals Inc Correlación - Moneda/Commodity
Rigel Pharmaceuticals Inc Finanzas
Annual | 2023 |
Ingresos: | $116.88M |
Beneficio Bruto: | $109.77M (93.92 %) |
EPS: | $-0.140 |
FY | 2023 |
Ingresos: | $116.88M |
Beneficio Bruto: | $109.77M (93.92 %) |
EPS: | $-0.140 |
FY | 2022 |
Ingresos: | $120.24M |
Beneficio Bruto: | $118.49M (98.55 %) |
EPS: | $-0.360 |
FY | 2021 |
Ingresos: | $149.24M |
Beneficio Bruto: | $148.15M (99.27 %) |
EPS: | $-0.110 |
Financial Reports:
No articles found.
Rigel Pharmaceuticals Inc
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico